Urolog. pro Praxi, 2009; 10(5): 279-281

Benign prostatic hyperplasia - combination treatment with alpha blockers and 5-alpha-reductase inhibitors

MUDr. Martin Lukeš, MUDr. Jiří Heráček
Urologická klinika 3. LF UK a FN KV v Praze

Benign prostatic hyperplasia (BPH) is the most common benign tumour in elderly men. The clinical manifestation of this disease

in the form of lower urinary tract symptoms (LUTS) reduces the quality of life of patients. The authors summarize the current options

and trends in treating benign prostatic hyperplasia and specify the role of individual drug groups, particularly their possible

combinations in treating BPH.

Keywords: benign prostatic hyperplasia, medication therapy, alpha blockers, 5-alpha-reductase inhibitors.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukeš M, Heráček J. Benign prostatic hyperplasia - combination treatment with alpha blockers and 5-alpha-reductase inhibitors. Urol. praxi. 2009;10(5):279-281.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barry JJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. Go to original source... Go to PubMed...
    2. Kolombo I. EUNI - Benigní hyperplazie prostaty. www.euni.cz.
    3. Berges RR, Pientka L. Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 1999; 36(Suppl 3): 21-27. Go to original source... Go to PubMed...
    4. Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH. The international prostate symptom score in a community-based sample of men between fifty-five and seventy-four years of age. Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 622-630. Go to original source... Go to PubMed...
    5. Lukeš M, Záleský M, Urban M. Nové trendy v konzervativní léčbě benigní hyperplazie prostaty. Urolog. pro Praxi, 2006; 7(1): 12-14.
    6. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36(1): 1-13. Go to original source... Go to PubMed...
    7. De la Rosette J, Madersbacher S, Alivizatos G. Guidelines on benign prostatic hyperplasia. In: Urological guidelines EAU March 2004 Edition; 7: 53.
    8. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; Suppl 2: 33-50. Go to original source... Go to PubMed...
    9. Kirby RS, et al. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media 1996.
    10. Silver RI, Wiley EL, Thigpen AE, et al. Cell type specific expression of steroid 5alfa-reductase 2. J Urol 1994; 152: 438-442. Go to original source... Go to PubMed...
    11. Matsumoto AM, Tenover L, McClung M, et al. PLESS Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002; 167: 2105-2108. Go to original source... Go to PubMed...
    12. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5alfa-reductase, supresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endo Metab 1992; 74: 505-550. Go to original source...
    13. Andriole GL, Guess HA, Epstein JL, et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195-201. Go to original source... Go to PubMed...
    14. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405. Go to original source... Go to PubMed...
    15. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999; 4: 670-678. Go to original source... Go to PubMed...
    16. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-563. Go to original source... Go to PubMed...
    17. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BHP treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37: 528-536. Go to original source... Go to PubMed...
    18. Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000; 163: 496-498. Go to original source... Go to PubMed...
    19. Wessells H, Roy J, Bannow J, et al. PLESS Study Group. Incidence and severity of sexual adverse experiences in finasterides and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-584. Go to original source... Go to PubMed...
    20. Andriole GL, Kirby R. Safety and tolerability of the Dual 5 alpha-Reductase Inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-88. Go to original source... Go to PubMed...
    21. Debruyne FM, Jardin A, Colloi D. Sustained release alfuzosin, finasteride and the combination of both in the treatment of benign prostate hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34: 169-175. Go to original source... Go to PubMed...
    22. Lepor H, Williford WO, Barry MJ, et al. Veterans affairs kooperative studies benign prostatic hyperplasia study group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-539. Go to original source... Go to PubMed...
    23. Kirby RS, Roehrborn CG, Boyle P, et al. Prospective european doxazosin and combination therapy study investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective european doxazosin and combination therapy (PREDICT) trial. Urology 2003; 61: 119-126. Go to original source... Go to PubMed...
    24. McConnell JD, Roehrborn CG, Bautista OM, et al. Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of the benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398. Go to original source... Go to PubMed...
    25. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial cobination therapy with the dual alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-466. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.